CARLOS MANUEL
PANIZO SANTOS
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (15)
2023
-
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study
British Journal of Haematology, Vol. 202, Núm. 4, pp. 776-784
2022
-
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100
-
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
Haematologica, Vol. 107, Núm. 11, pp. 2675-2684
2021
-
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients
Annals of Hematology, Vol. 100, Núm. 4, pp. 1023-1029
2020
-
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Blood, Vol. 135, Núm. 13, pp. 996-1007
2018
-
Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma
Oncotarget, Vol. 9, Núm. 64, pp. 32383-32399
2017
-
Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)
Haematologica, Vol. 102, Núm. 2, pp. 235-245
-
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma
Blood
2016
2015
-
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 7, pp. 398-403
2014
-
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial
The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111
2013
2012
-
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain
Leukemia Research, Vol. 36, Núm. 6, pp. 709-714
2009
-
Efficacy and safety of Liposomal cytarabine in lymphoma Patients with central nervous system involvement from lymphoma
Cancer, Vol. 115, Núm. 9, pp. 1892-1898
2003
-
Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized, double-blind clinical trial
Journal of Thrombosis and Haemostasis, Vol. 1, Núm. 3, pp. 425-432